BackINmune Bio Overview

INmune Bio Current Cash

INmune Bio's current cash is $18M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$18.41M
↓ 44.83% YoYΔ $-14.96M vs prior year quarter

Peer trimmed avg / median

Loading

INmune Bio Current Cash History

Loading

INmune Bio vs. peers: Current Cash Comparison

Loading

INmune Bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

INmune Bio (INMB) FAQ

As of the most recent data (June 2026), INMB shows a current cash of $18M. That compares with $33M in the prior-year period — down 44.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INMB's current cash is now $18M (was $33M) — a 44.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether INmune Bio is outperforming or lagging.

Tracking INMB's current cash over time shows whether INmune Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $18M That compares with $33M in the prior-year period — down 44.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has INmune Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $18M) with ownership activity and broader fundamentals.

INmune Bio's current cash is $18M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.